In general, the results of such studies support those of the major outcomes trials, even though in most countries, SGLT2 inhibitors are not prescribed in patients with eGFR < 60 mL/min/1.73 m2, limiting the possibility to extend these observations to a T2D population at higher renal risk. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.